Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
25.95
-0.39 (-1.48%)
Mar 6, 2026, 4:00 PM EST - Market closed
Centessa Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Centessa Pharmaceuticals stock have an average target of 39.5, with a low estimate of 27 and a high estimate of 62. The average target predicts an increase of 52.22% from the current stock price of 25.95.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Centessa Pharmaceuticals stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 5 | 5 | 6 | 5 | 4 |
| Buy | 4 | 4 | 4 | 5 | 5 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 9 | 9 | 11 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy Initiates $40 | Buy | Initiates | $40 | +54.14% | Feb 24, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $33 → $38 | Strong Buy | Maintains | $33 → $38 | +46.44% | Jan 29, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $30 → $33 | Strong Buy | Maintains | $30 → $33 | +27.17% | Jan 8, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +15.61% | Jan 2, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $40 → $62 | Buy | Maintains | $40 → $62 | +138.92% | Dec 10, 2025 |
Financial Forecast
Revenue This Year
16.08M
Revenue Next Year
n/a
from 16.08M
EPS This Year
-1.41
from -2.06
EPS Next Year
-1.67
from -1.41
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 25.4M | n/a | ||||
| Avg | 16.1M | n/a | ||||
| Low | 14.7M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.39 | -1.46 | ||||
| Avg | -1.41 | -1.67 | ||||
| Low | -1.47 | -1.91 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.